Antiangiogenic therapies in endometriosis
- 1 September 2006
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 149 (2) , 133-135
Abstract
Oral contraceptives, androgenic agents, progestins and gonadotropin‐releasing hormone analogues have all been successfully used in the treatment of endometriosis. However, none of these drugs can eradicate the disease. It is widely accepted that the growth of newly formed blood vessels is essential for the establishment and growth of endometriotic lesions; therefore, inhibition of angiogenesis may offer a new option for treatment of this disorder. In this paper, we reviewed anti‐vascular endothelial growth factor agents and other angiostatic drugs (i.e., TNP470, endostatin, anginex, rapamycin) that have been studied in laboratory and animal models of endometriosis. Although preliminary results are interesting, further investigations are required before clinical trials can be planned in humans.British Journal of Pharmacology (2006) 149, 133–135. doi:10.1038/sj.bjp.0706860Keywords
This publication has 20 references indexed in Scilit:
- Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferationBritish Journal of Pharmacology, 2006
- Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse modelFertility and Sterility, 2006
- Future Perspectives in the Medical Treatment of EndometriosisObstetrical & Gynecological Survey, 2005
- Sirolimus: Its role in nephrology (Review Article)Nephrology, 2005
- In vivo analysis of angiogenesis in endometriosis-like lesions by intravital fluorescence microscopyFertility and Sterility, 2005
- Endostatin inhibits the growth of endometriotic lesions but does not affect fertilityFertility and Sterility, 2005
- Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membraneFertility and Sterility, 2005
- Clinical application of sirolimus in renal transplantation: an updateTransplant International, 2005
- Sirolimus: a new option in transplantationExpert Opinion on Pharmacotherapy, 2005
- Orthotopic liver transplantation using low-dose tacrolimus and sirolimusLiver Transplantation, 2001